Epitalon vs DSIP, SS-31, NAD+ and Endoluten related to longevity

Epitalon, DSIP, SS-31, NAD+ and Endoluten are often grouped together under terms such as „longevity” or „biohacking”, but they are not equivalent compounds and do not address the same research questions. Epitalon has been studied primarily in the context of telomere biology and the pineal gland, DSIP in sleep research, SS-31/elamipretide in the context of mitochondrial function, NAD+ in cellular metabolism, and Endoluten as a pineal-derived peptide complex for which the evidence base is considerably less unambiguously indexed. [1–8]

The broad category of „longevity-associated compounds” can conceal significant differences in chemistry, mechanism of action, quality of evidence, and degree of clinical development. Epitalon is a defined tetrapeptide Ala-Glu-Asp-Gly (AEDG). DSIP, or delta sleep-inducing peptide, is a nine-amino-acid neuropeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. SS-31, now more commonly referred to clinically as elamipretide, is a mitochondria-targeted tetrapeptide that interacts with cardiolipin in the inner mitochondrial membrane. NAD+ is not a peptide: nicotinamide adenine dinucleotide is an essential metabolic cofactor involved in redox reactions, energy metabolism, and signalling. Endoluten is generally described in the tradition of Khavinson products as a low-molecular-weight pineal peptide complex rather than a single, chemically defined peptide. [1,6–9]

These differences have significant consequences for the interpretation of evidence. A sleep study involving DSIP cannot be used to confirm the effects of Epitalon. Research on elamipretide in mitochondrial diseases cannot be treated as evidence of the efficacy of a general „mitochondrial peptide stack”. Human studies showing that nicotinamide riboside or nicotinamide mononucleotide can increase the levels of NAD-related metabolites do not prove that intravenous NAD+ extends lifespan. Similarly, findings concerning Epitalon or the older pineal extract Epithalamin should not be automatically attributed to Endoluten simply because all three appear in related discussions concerning pineal peptides.

Therefore, the most useful comparison is not to ask which compound is the „best longevity peptide”, but rather which biological question was actually investigated for each compound, what level of evidence exists, and whether these results have translated into clinically relevant effects in humans.

How does Epitalon compare to DSIP?

Epitalon and DSIP are structurally and scientifically distinct peptides. Epitalon is the tetrapeptide AEDG studied mainly in the context of telomere biology, pineal gland function, melatonin, chromatin and ageing models, whereas DSIP is the nonapeptide WAGGDASGE studied primarily with regard to sleep physiology and neuroendocrine effects. DSIP has been the subject of direct human sleep studies, although their results were limited and inconsistent. [1–5]

Epitalon consists of four amino acids — Ala-Glu-Asp-Gly — and stems from Khavinson's research programme into pineal peptides. Its most recognisable evidence includes studies on telomerase and telomeres in cultured human cells, age-related melatonin regulation in animal studies and limited human studies, effects on chromatin in cultured lymphocytes, and lifespan or cancer-related outcomes in animal models. [1,10–13] The preclinical literature is relatively extensive, but contemporary controlled data on human efficacy remain limited.

DSIP has a completely different structure and research history. Schoenenberger and co-workers identified it as the nonapeptide Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, abbreviated as WAGGDASGE, during research on a sleep-associated factor in rabbits. [2] The term „delta sleep-inducing peptide” originated from early electrophysiological experiments in which this substance was linked to slow-wave, or delta, EEG activity.

Unlike many research peptides currently discussed within longevity communities, DSIP was directly tested on humans for sleep several decades ago. In a 1981 double-blind, cross-over study involving six healthy volunteers, intravenous administration of DSIP was associated with an increase in the amount of sleep during the observation period and with certain changes in subsequent nocturnal sleep measurements. [3]

Later research, however, made the clinical picture significantly less convincing. A double-blind study involving 16 people with chronic insomnia showed slightly greater sleep efficiency and shorter sleep latency compared with placebo, but the researchers emphasised that the statistically significant changes were small, resulted partly from changes in the placebo group, and were not accompanied by a consistent improvement in other objective or subjective outcomes. The authors concluded that short-term use of DSIP is unlikely to provide significant therapeutic benefits in chronic insomnia. [4]

Another controlled clinical trial also reported an increase in total sleep time and NREM sleep, but stated that the observed improvement was of little clinical significance, partly because significant differences between the groups already existed at baseline. [5]

Detailed sleep results are more complex than the peptide's name suggests. In an early insomnia experiment involving six people, the apparent sleep-promoting effect appeared mainly in the second hour, rather than causing immediate and predictable sedation. Later controlled studies showed that the increase in NREM sleep resulted primarily from an increase in stage 2 sleep, whereas stages 3 and 4 of slow-wave sleep and REM sleep did not increase consistently. In an insomnia study involving 16 people, moderate objective changes were not accompanied by an improvement in subjective sleep quality. [3–5]

This discrepancy between objective and subjective outcomes is significant. Polysomnography can detect changes in sleep latency, sleep efficiency, awakenings and the distribution of sleep stages, but a statistically measurable change does not necessarily mean that sleep is perceived as more restorative or that daytime functioning improves. The historical literature concerning DSIP has failed to demonstrate sustained improvement in contemporary clinical outcomes, such as insomnia severity, daytime alertness, quality of life or sustained remission.

The mechanism of action also remains uncertain. The existence of a dedicated DSIP receptor or a single signalling pathway has not been confirmed. Experimental studies suggest possible modulation of GABAergic, glutamatergic, monoaminergic processes and the hypothalamic–pituitary–adrenal axis, but a significant portion of this evidence comes from animal tissue studies, isolated neurones or specialised neuroendocrine experiments, rather than from unambiguous receptor pharmacology in humans. [17]

Statements regarding the half-life of DSIP require similar caution. The frequently repeated value of around 15 minutes comes from in vitro degradation studies in brain tissue rather than from a validated human plasma pharmacokinetic study. Therefore, it cannot be reliably used to predict how quickly DSIP works, how long the effect lasts, or how frequently administration would be necessary.

The route of administration used in clinical studies represents another significant limitation. The main human sleep studies used DSIP administered intravenously under supervision. These studies do not determine the bioavailability, efficacy or safety of modern subcutaneous injections, nasal sprays or oral products. There are no direct comparative human studies showing that the nasal or subcutaneous formulation reproduces the exposure or sleep effects observed following historical intravenous administration.

Native DSIP must also be distinguished from phospho-DSIP. Phospho-DSIP is a modified analogue phosphorylated at the serine residue in position 7. In studies on rats, changes in slow-wave sleep and paradoxical sleep, i.e. REM, were reported following the administration of this analogue, but these results cannot be automatically attributed to unmodified DSIP nor translated into clinical effects in humans.

This creates an unusual comparative situation. DSIP has more direct human sleep studies than Epitalon, but this literature is old, relies on small samples and yields inconsistent results. Epitalon's sleep-related evidence is less direct and focuses more on melatonin and circadian rhythm regulation rather than polysomnographically measured insomnia outcomes.

It would therefore not be correct to describe Epitalon and DSIP as two versions of the same „sleep peptide”. Their areas of overlap are limited and relate primarily to the broader field of neuroendocrine and circadian rhythm research.

Do Epitalon and DSIP address the same research questions?

Only to a limited extent. DSIP research is more concerned with direct issues relating to sleep architecture, sleep latency, EEG activity and neurophysiological regulation, whereas Epitalon research focuses more on pineal gland function, melatonin rhythms, telomerase, gene regulation and the biology of ageing. Both areas intersect with circadian rhythm physiology, but their main experimental goals and evidence bases differ significantly. [1,3–5,14–16]

The clearest area of overlap is the biology of sleep and circadian rhythms, although even here the measured outcomes differ.

DSIP research has frequently evaluated actual sleep parameters. Human studies have utilised objective or semi-objective endpoints, such as total sleep time, sleep efficiency, sleep latency, NREM sleep, and other polysomnographic parameters. [3–5] Early animal studies also assessed EEG activity and individual sleep stages. For this reason, DSIP can reasonably be described as a peptide with a direct history of sleep research, even though clinical evidence has not confirmed its efficacy as a modern treatment for insomnia.

In these studies, DSIP did not produce a single consistent pattern of changes to sleep architecture. Some early experiments suggested longer or less interrupted sleep, whereas later controlled studies showed weak or statistically insignificant effects. When an increase in NREM sleep was observed, the change did not consistently involve deeper slow-wave sleep. Results regarding REM sleep were also inconsistent. Consequently, DSIP cannot be accurately described as a compound proven to increase „deep sleep”, restore a specific sleep stage, or act like a conventional sleeping pill. [3–5]

Epitalon research typically approaches the issue of sleep at an earlier level of regulation. In studies on older rhesus macaques, changes in nighttime or evening melatonin levels and certain aspects of the circadian cortisol rhythm were noted following exposure to Epithalon. [14] A study on rat pinealocytes found increased expression or activation of molecular elements involved in melatonin synthesis, along with increased melatonin production in culture. [15]

However, the literature on Epitalon also contains conflicting results. Djeridane and co-workers studied isolated pineal glands from young and old rats and found no significant increase in basal or stimulated melatonin secretion after exposure to AEDG [16]. For this reason, it is not appropriate to describe Epitalon simply as a reliable melatonin-increasing compound.

Crucially, melatonin concentration is not the same result as sleep quality. The literature regarding Epitalon does not confirm significant improvement in humans regarding:

sleep efficiency;

intensification of insomnia;

snu REM;

deep or slow-wave sleep;

total sleep time;

night-time awakenings; nor

daytime functioning resulting from improved sleep.

For comparison, the DSIP studies measured some of these sleep parameters directly, although the results were not consistently clinically significant.

Their broader research profiles differ even more. Epitalon has been the subject of research on human cells regarding telomerase and telomere length, whereas telomere maintenance is not a characteristic area of research for DSIP. DSIP has a broader historical neurophysiological literature concerning neurotransmission, stress response, hormonal regulation, and models related to withdrawal syndrome, but these results do not support its action as a geroprotective compound. [17]

Neuroendocrine literature encompasses experiments concerning ACTH, cortisol, corticosterone and responses to stress-related stimuli. These results suggest that DSIP may influence the hypothalamic–pituitary–adrenal axis under specific experimental conditions, but do not prove that it reliably lowers cortisol levels in humans. Similarly, proposed effects involving GABA, glutamate, NMDA signalling, serotonin or opioid-related systems remain mechanistic observations rather than proof of a single, coherent therapeutic mechanism. [17]

Safety evidence is also too limited to support claims of use in longevity. Historical human exposure has been short-term and has mainly involved intravenous administration. Transient headaches, nausea, dizziness, sweating and hypotension have been reported in some clinical settings, whereas few or no adverse events were reported in a few small sleep studies. These results do not confirm long-term safety and do not account for the additional risks regarding identity, purity, sterility, endotoxins and contaminants in the case of unapproved investigational products.

Epitalon can therefore be more accurately characterised as a research peptide related to ageing, the pineal gland and telomeres, with some overlap into circadian rhythm research, whereas DSIP is primarily a research peptide related to sleep and neuroregulation, which was later incorporated into the discussion on longevity.

A more detailed discussion of Epitalon and the biology of the circadian rhythm can be found in the article Epitalon Sleep Research: Melatonin, Circadian Rhythm and Timing.

How does Epitalon compare to SS-31?

Epitalon and SS-31 concern fundamentally different areas of biology. Epitalon is studied primarily in the context of telomeres, the pineal gland, and pathways related to ageing, whereas SS-31 — elamipretide — is a mitochondria-targeted tetrapeptide that interacts with cardiolipin and has undergone numerous human clinical trials. Elamipretide currently holds FDA accelerated approval for a specific mitochondrial disease, rather than for general longevity. [1,6,18–23]

SS-31 is also known as elamipretide, and was previously referred to as Bendavia or MTP-131. Although both Epitalon and SS-31 are tetrapeptides, their shared number of amino acids constitutes almost the entirety of their similarity.

Elamipretide was developed based on mitochondrial biology. Mechanistic studies have shown interactions with cardiolipin, a phospholipid concentrated in the inner mitochondrial membrane. Experimental studies have demonstrated that SS-31 can influence the interaction of cytochrome c with cardiolipin, preserve electron transfer function and improve the efficiency of mitochondrial ATP synthesis under appropriate experimental conditions. [18]

Epitalon has sometimes been discussed in the context of oxidative stress and mitochondrial function, but mitochondrial cardiolipin is not its primary mechanistic target. Its research programme focuses instead on telomerase, chromatin, melatonin, the physiology of ageing, and transcription-related mechanisms. [1]

The difference in clinical development is even greater.

Elamipretide has been evaluated in randomised controlled trials in humans across several different disease states. A dose-escalation study in adults with primary mitochondrial myopathy showed a dose-dependent improvement in the 6-minute walk test distance following short-term treatment, although several other outcomes did not differ significantly, and the authors considered larger studies to be necessary. [19]

A subsequent randomised crossover study in primary mitochondrial myopathy showed no consistent benefit in the broader clinical programme, demonstrating that even a mechanism-targeted mitochondrial drug can produce mixed clinical results. [20]

Among patients with heart failure with reduced ejection fraction in the Phase 2 PROGRESS-HF trial, 71 participants were randomised to placebo or one of two doses of elamipretide for 28 days. Elamipretide was well tolerated, but did not significantly improve the primary left ventricular structural endpoint compared with placebo. [21]

Other human studies have yielded more promising mechanistic results. Among 39 older adults selected for impaired mitochondrial function, a randomised, double-blind study showed that a single exposure to elamipretide increased, compared with placebo, a parameter of skeletal muscle mitochondrial ATP-producing capacity. [22]

A significant regulatory development occurred in September 2025, when the FDA granted accelerated approval to Forzinity (elamipretide) for Barth syndrome in patients weighing at least 30 kg. Barth syndrome is a rare mitochondrial disorder associated with abnormal cardiolipin metabolism. The approval was based on a very small clinical programme and requires confirmatory data; it should not be interpreted as FDA approval of elamipretide in the context of ageing or longevity.

This gives SS-31/elamipretide a significantly more advanced human clinical development profile than Epitalon in the field of mitochondrial diseases. However, this does not confirm elamipretide as a human life-extension drug.

The difference can be summarised as follows:

Epitalon → telomere/pineal/ageing research

SS-31/elamipretide → mitochondrial cardiolipin and bioenergetics research

None of these evidence bases confirms a general extension of human life.

How does Epitalon compare to NAD+?

Epitalon and NAD+ are fundamentally different compounds: Epitalon is a synthetic tetrapeptide studied experimentally in telomere and pineal gland biology, whereas NAD+ is an endogenous dinucleotide essential for cellular redox reactions, energy metabolism, and signalling. NAD-directed strategies have a considerably more extensive contemporary human research literature, particularly in the case of NR and NMN, but demonstrated anti-ageing benefits remain limited. [1,7,24–27]

The first important difference is the chemical structure: NAD+ is not a peptide.

Nicotinamide adenine dinucleotide is a cellular coenzyme involved in electron transfer and energy metabolism. It also serves as a substrate for enzymes such as sirtuins and PARPs, and processes associated with CD38, linking NAD metabolism with DNA repair, stress responses, metabolism and the biology of ageing.

This creates a certain conceptual similarity to Epitalon, as both compounds are discussed in relation to cellular ageing, but their underlying mechanisms are very different.

The most well-known mechanistic findings regarding Epithalon include telomerase activation or telomere elongation in human cells, observations related to melatonin, chromatin changes, and hypotheses concerning gene regulation. [10–13]

NAD+-targeted ageing research focuses more on cellular energy metabolism and metabolic signalling. Preclinical studies have repeatedly shown that increasing NAD availability can affect mitochondrial function, glucose and lipid metabolism, inflammatory signalling, and age-related physiology. However, translating these findings into effects in humans has been considerably less spectacular. [24–27]

The main source of misunderstanding is the fact that NAD+ itself, NR, and NMN are not interchangeable interventions.

Most modern clinical human data involves precursors — nicotinamide riboside and nicotinamide mononucleotide — rather than intravenously administered NAD+ itself. Human studies have repeatedly demonstrated that oral NR or NMN can increase the levels of NAD-related metabolites in the blood and certain tissues, confirming a clear effect on the biochemical target. [24–27]

Evidence regarding significant functional effects is considerably less consistent.

A review published in 2025 in Nature Metabolism stated that although NAD precursor supplementation has strong support in preclinical research, clinical efficacy regarding healthy ageing remains limited so far, with human results being few and tissue-dependent. [24]

A 2026 systematic review evaluated 113 studies, including 33 human interventions. It found that oral NR and NMN generally increased NAD-related biomarkers and were relatively well tolerated over short and medium terms, but the impact on functional, vascular, metabolic and other healthspan-related outcomes was inconsistent and often null or limited to specific endpoints. The review did not identify any eligible outcome studies on intravenous or intramuscular NAD+ administration alone for anti-ageing or wellness applications. [25]

The statement that „NAD+ has stronger evidence in humans than Epitalon” therefore requires clarification.

It can reasonably be stated that NAD-targeted biology, particularly NR and NMN supplementation, has been investigated in a greater number of contemporary randomised human trials.

However, it is not correct to state that it has been proven that NAD+ slows down ageing or extends human life.

Both compounds also focus on different endpoints. Epitalon has more direct experimental evidence regarding telomere maintenance, whereas NAD+ precursors have more human biomarker research related to metabolism and NAD. Neither of them has been shown to extend human lifespan.

A more detailed comparison of NAD-related compounds and peptide-based approaches can be found in the directly linked article NAD+ vs Other Longevity Compounds.

How does Epitalon compare to Endoluten?

Epitalon is a chemically defined synthetic tetrapeptide AEDG with identifiable peer-reviewed literature, whereas Endoluten is generally described as a low molecular weight peptide complex derived from the pineal gland rather than a single defined molecule. Direct peer-reviewed evidence indexed specifically under the name Endoluten is limited, therefore results concerning Epitalon or Epithalamin should not be automatically attributed to Endoluten.

This comparison requires special caution, as Endoluten, Epitalon and Epithalamin are often conflated in online materials.

Epitalon is chemically distinct. It is Ala-Glu-Asp-Gly, or AEDG, and its identity can be determined through sequence and molecular analysis. AEDG was developed based on research involving the older pineal gland preparation Epithalamin, and was subsequently identified within the pineal polypeptide complex. [1,28]

Epithalamin is something different. It is a complex peptide preparation derived from the bovine pineal gland, rather than a single defined molecule composed of four amino acids. Many older human gerontological and endocrinological research results, widely associated with „pineal peptides”, actually concern Epithalamin rather than Epitalon.

Endoluten introduces an additional layer of uncertainty. The brand name is used in reference to a pineal gland peptide complex, but targeted searches in PubMed have not identified a comparable base of indexed, peer-reviewed primary publications investigating specifically „Endoluten” as a separately characterised intervention.

This distinction is important, as three separate claims are often treated as if they were equivalent:

Epithalamin affected result X.

AEDG/Epitalon affected the result of X.

Therefore, Endoluten must affect result X.

Such a conclusion is not scientifically justified unless the Endoluten preparation itself has been characterised and directly tested.

The same issue applies to claims related to melatonin. Epitalon has animal, primate, and limited human studies involving melatonin. Epithalamin has its own historical endocrinological literature. This does not prove that the commercial preparation Endoluten provides equivalent exposure to peptides, reaches the same tissues, or reproduces the same biological effect.

A reliable evidence base regarding Endoluten should ideally specify:

peptide composition of the preparation;

batch-to-batch consistency;

identity and quantity of individual active peptides;

pharmacokinetics specific to oral administration or other routes of administration;

do intact peptides reach the systemic circulation;

results of controlled clinical trials in humans; and

long-term security.

Without this data, Endoluten is best described as an associated pineal peptide complex with significantly less directly attributable peer-reviewed evidence than the chemically defined AEDG Epitalon.

Have any of these connections been studied directly?

No robust peer-reviewed evidence has been identified regarding fixed combinations of Epitalon with DSIP, SS-31, NAD+ or Endoluten. Each of these compounds has been largely studied within its own research programme, therefore claims that the combinations are synergistic, safer, more effective or better for longevity cannot be confirmed by simply adding up the proposed mechanisms of the individual compounds.

This is particularly important for searched phrases such as „Epithalon + DSIP”, „Epitalon DSIP stack”, „Epitalon and SS-31” or combinations involving peptides and NAD+.

A search query may indicate market or user interest, but it does not prove that the combination itself has ever been scientifically evaluated.

In the case of Epitalon and DSIP, the theoretical rationale generally stems from their overlap in the biology of circadian rhythms. Epitalon is associated with pineal gland and melatonin research, whereas DSIP has a direct history of sleep research. This does not prove that combining them improves sleep more than either of these compounds used separately.

There is no established study showing:

Epitalon alone compared to DSIP alone;

both peptides used together;

appropriately matched placebo control;

polysomnographic results;

pharmacokinetic interactions; nor

connection security.

Similarly, the combination of Epitalon and SS-31 might seem conceptually appealing, as one compound is promoted in the context of broader ageing biology, while the other has a direct mitochondrial mechanism. However, there is no direct evidence showing that AEDG enhances the mitochondrial effects of elamipretide or that elamipretide increases the telomere-related effects observed with Epitalon.

The same principle applies to NAD+.

Mitochondria, NAD metabolism and telomere maintenance are involved in the biology of ageing, but the biological pathways are connected in ways that can be additive, redundant, compensatory or antagonistic. Mechanistic complementarity is a hypothesis, not proof of synergy.

A rigorous combination experiment would need to compare each intervention separately with their combination under the same experimental conditions. For example, an Epitalon–DSIP study should ideally include a control group, Epitalon alone, DSIP alone, and the combined treatment, with pre-specified outcomes regarding sleep or circadian rhythm. Similar factorial designs would be required for Epitalon with elamipretide or Epitalon with a NAD-targeting intervention.

Endoluten presents an additional difficulty because it is itself a complex mixture rather than a single fully characterised molecular entity. Combining a defined peptide with a poorly characterised peptide complex further complicates the attribution of biological effects.

Consequently, statements such as „Epitalon and DSIP act synergistically”, „SS-31 complements Epitalon's longevity stack” or „adding NAD+ enhances Epitalon's anti-ageing effect” require direct evidence, which is currently lacking.

Which compound has the strongest evidence in humans for the individual outcomes?

No single compound has the strongest evidence across all longevity-related outcomes. DSIP has the most direct historical human sleep experiments, elamipretide has the strongest clinical evidence in mitochondrial disease, NAD precursors have the largest contemporary human biomarker literature, and Epitalon has characteristic telomere-related evidence derived from human cell studies. None of them have demonstrated human lifespan extension.

The response changes depending on the measured result.

You

In the case of direct human sleep measurements, DSIP has the most robust evidence among these compounds, as controlled studies have evaluated sleep latency, sleep efficiency, NREM sleep, and related outcomes following DSIP administration. [3–5]

However, the term „strongest” in this context should not be equated with „strong”. The studies were small and old, and subsequent analyses indicated that the observed clinical effects were weak or had limited therapeutic significance.

Epitalon has more evidence related to melatonin and the endocrine physiology of the circadian rhythm, but less direct data regarding sleep quality in humans.

Melatonin and pineal gland ageing

Epitalon has more appropriate experimental literature, particularly concerning older monkeys and pineal cell studies. [14–16] Some older human studies have also reported changes in nocturnal melatonin levels in older people, although the methodological details available in the abstracts are limited.

DSIP should not be automatically classified as a melatonin peptide solely due to its connection with sleep.

Telomerase and telomere maintenance

Epitalon has the strongest direct evidence in this group, with the important caveat that the strongest results come from in vitro studies on human cells rather than controlled human treatment trials.

A 2003 experiment on fibroblasts noted telomerase activation and telomere lengthening, while a 2025 study by Al-Dulaimi replicated the telomere-related effects in normal and cancer human cell lines using more contemporary molecular methods. [10,11]

There are still no controlled clinical trials showing significant telomere lengthening in humans after the use of Epitalon.

Mitochondrial bioenergetics

Elamipretide/SS-31 definitely has the strongest direct evidence in humans.

Human studies have measured mitochondrial ATP production capacity, exercise capacity, cardiac outcomes, and clinical endpoints in primary mitochondrial diseases. [19–23]

Most importantly, in 2025 elamipretide became an FDA-approved drug under the accelerated approval pathway for a specific subgroup of patients with Barth syndrome.

This approval is disease-specific. It does not confirm a role in healthy ageing, general enhancement of mitochondrial function, or life extension.

NAD metabolism

NAD-targeted approaches have the strongest evidence in humans regarding the direct alteration of NAD-related biomarkers.

Numerous human studies on NR and NMN show an effect on the biochemical target, in particular an increase in NAD-related metabolites in the blood. [24–27]

However, a gap remains between biomarker change and healthspan improvement. Functional outcomes remain inconsistent, which is why the latest reviews still describe anti-ageing efficacy in humans as unproven.

Human longevity

Regarding the actual extension of human life, none of these compounds have convincing evidence.

Epitalon has animal longevity research, but in some models the effects mainly concerned maximum survival or late-life survival rather than mean lifespan, whilst other models showed limited effects.

NAD precursors have an extensive base of gerontological research in animals, but an extension of human lifespan has not been demonstrated.

Elamipretide has an advanced, disease-specific clinical development programme, but no longevity study has been conducted showing a longer lifespan for healthy people.

DSIP has a history of sleep research, not longevity evidence.

Endoluten does not have a sufficiently clearly indexed evidence base to confirm its effect on longevity in humans.

Comparison of evidence at a glance

The table shows why classifying these compounds as if they were competing for the same outcome can lead to erroneous conclusions.

Which compound has generally the strongest evidence in humans?

If „strongest evidence in humans” means the most advanced conventional clinical development programme, elamipretide clearly stands out. It has undergone Phase 2 and Phase 2/3 trials, has long-term observational data in humans with a rare mitochondrial disease, and received accelerated FDA approval in 2025 for Barth syndrome. [19–23]

This does not mean it is the strongest longevity-related intervention. Its strongest evidence relates to a specific mitochondrial disease, rather than the slowing of normal ageing.

When it comes to evidence on human metabolic biomarkers, NAD precursors like NR and NMN have the largest contemporary base of clinical research. Reviews now encompass dozens of human interventions, and repeated evidence shows that biomarkers associated with NAD can be increased. [24–27] The uncertainty lies in whether changes in these biomarkers consistently translate into meaningful improvements in healthspan.

When it comes to sleep, DSIP has more direct human studies than Epitalon, although this evidence is much weaker by modern clinical standards. [3–5]

The apparent advantage relates directly to the immediacy of measurements, rather than proof of efficacy. DSIP studies evaluated sleep itself, but were small, used historical intravenous protocols, and yielded conflicting objective and subjective results. They do not determine a reliable onset of action, confirm the efficacy of a modern nasal or subcutaneous product, or support long-term use in insomnia.

Regarding telomere biology, Epitalon has more direct experimental evidence, but the strongest significant results remain cellular rather than clinical. [10,11]

With Endoluten, the main issue is the attribution of evidence. Without a clearly indexed set of peer-reviewed clinical studies specific to Endoluten and a detailed molecular characterisation, claims originating from studies on Epitalon or Epithalamin should not be considered direct evidence regarding Endoluten.

Do stronger mechanistic evidence mean better longevity evidence?

No. A compound may have a clearly demonstrated biological mechanism without simultaneously showing an effect on human ageing or lifespan. Telomere length, mitochondrial ATP production, NAD concentrations, melatonin rhythms and sleep architecture are various surrogate endpoints, and a change in one biomarker does not automatically mean the extension of human life or the slowing down of ageing.

This principle is key when comparing compounds associated with longevity.

Elamipretide is a clear example. The peptide has a well-developed mitochondrial mechanism involving cardiolipin and has demonstrated a measurable impact on mitochondrial bioenergetics in humans. [18,22] Its clinical development has also advanced far enough to have gained regulatory approval for a specific disease. Neither of these facts proves an extension of lifespan in healthy adults.

NAD research shows the same distinction. NR and NMN can consistently alter NAD-related metabolites in humans, while improvements in glucose metabolism, muscle function, vascular outcomes and other parameters related to healthspan remain inconsistent. [24–27]

Epitalon shows a translational problem from a different perspective. The peptide may influence telomere maintenance pathways in cultured cells, but between a telomere assay in fibroblasts and the extension of human lifespan there is still a large gap.

Similarly, DSIP shows that even a direct impact on sleep-related physiology does not necessarily translate into a clinically useful treatment for sleep disorders.

Therefore, the most scientifically justified comparison of compounds associated with longevity separates:

targeting the mechanistic target

from

physiological improvement

from

clinical benefit

from

healthy life expectancy improvements

from

life extension.

These results are not mutually interchangeable.

Frequently asked questions about Epitalon, DSIP, SS-31 and NAD+

Is DSIP better than Epitalon for sleep?

DSIP has more direct human sleep studies, as controlled trials have measured sleep latency, sleep efficiency and parameters of individual sleep stages following DSIP administration. [3–5] However, the studies were small, and subsequent work showed that the clinical benefit was weak or of limited significance. Epitalon studies are more indirect and focus mainly on melatonin and circadian rhythm regulation rather than controlled insomnia outcomes.

The comparison therefore depends on the meaning of the word „better”. DSIP has a more direct history of sleep research, but neither of these peptides has been recognised as a modern approved treatment for insomnia. DSIP also lacks a confirmed receptor, a validated time of onset in humans, or demonstrated equivalence between the historically used intravenous route and products promoted for use via other routes.

Does DSIP reliably increase deep sleep?

There is consistent lack of evidence in humans showing that native DSIP reliably increases deep or slow-wave sleep. Some studies have reported changes in total sleep time or NREM sleep, but one controlled study showed that the increase was mainly in stage 2 rather than stages 3 and 4. Rat study results regarding phosphorylated DSIP relate to a chemically modified analogue and cannot support the effects of native DSIP in humans. [3–5]

Does DSIP lower cortisol levels?

Not in a predictable manner according to available evidence. Human and animal studies suggest that DSIP may affect the regulation of ACTH, cortisol, or corticosterone under specific experimental conditions, but they do not confirm a reliably cortisol-lowering action or a clinically validated mechanism for treating stress. [17]

What is the half-life of DSIP?

A validated human plasma elimination half-life has not been established. The frequently cited value of approximately 15 minutes originates from peptide degradation observed in an in vitro brain tissue system rather than a human pharmacokinetic study. It cannot be used as a clinical rule for timing or frequency of use.

Is phospho-DSIP the same as DSIP?

No. Phospho-DSIP is DSIP modified by phosphorylation at the Ser7 position. In selected studies on rats it induced sleep-related effects, but native DSIP and phospho-DSIP are separate research interventions. Evidence concerning one form should not be automatically applied to the other.

Can Epitalon and DSIP be combined?

No robust peer-reviewed study evaluating the combination of Epitalon and DSIP has been identified. Their distinct research profiles may provide a theoretical rationale for investigating such a combination, but no established evidence exists regarding synergy, optimal ratio, improved sleep outcomes, pharmacokinetic compatibility, or long-term safety of the combination.

Does DSIP extend life?

No extension of human life has been demonstrated with the use of DSIP. Its main historical research concerns sleep, electrophysiology, neuroendocrine signalling and related physiological functions, rather than controlled longevity outcomes. Its presence in contemporary discussions of „longevity peptides” should not, therefore, be interpreted as evidence that it extends human life.

Is SS-31 the same as elamipretide?

Yes. SS-31 is the developmental name commonly associated with the mitochondria-targeted peptide now known as elamipretide. Its best-understood mechanism involves cardiolipin and mitochondrial bioenergetics, and in 2025 the FDA granted elamipretide accelerated approval for a specific indication concerning Barth syndrome. [18,23]

Does SS-31 have proven anti-ageing effects?

No. Elamipretide has an extensive base of human mitochondrial studies and an approved indication for Barth syndrome, but it has not been recognised as an anti-ageing therapy or a method for extending human life. In a study involving older adults, an acute improvement in the energetic capacity of skeletal muscle mitochondria was observed, which represents a mechanistic physiological endpoint rather than evidence of slower ageing or lifespan extension. [22]

Is NAD+ a peptide?

No. NAD+ is nicotinamide adenine dinucleotide, a dinucleotide cofactor involved in cellular redox metabolism and signalling. Chemically and biologically, it differs from Epitalon, DSIP and elamipretide. Most modern human research on „NAD boosting” has evaluated precursors such as NR and NMN, rather than peptide compounds.

Does NAD+ have stronger research evidence than Epitalon?

NAD-directed approaches, particularly NR and NMN, have a larger contemporary clinical human literature and stronger evidence regarding the alteration of NAD-related biomarkers. Epitalon has distinctive cellular evidence concerning telomerase and telomeres, but significantly fewer contemporary clinical studies. Neither of these evidence bases supports human lifespan extension or clinically proven general anti-ageing effects.

Is Endoluten the same as Epitalon?

No. Epitalon is a chemically defined AEDG tetrapeptide. Endoluten is generally described as a low-molecular-weight peptide complex derived from the pineal gland, rather than as a single defined peptide. Evidence obtained using Epitalon or the older pineal preparation Epithalamin should not automatically be treated as direct evidence concerning Endoluten.

Which longevity-related peptide is the strongest?

None of the peptides discussed here have shown an overall extension of human lifespan. Elamipretide has the strongest conventional evidence regarding clinical development, but this relates to mitochondrial diseases rather than longevity. Epitalon has distinctive cellular studies related to telomeres, whereas DSIP has direct, yet weak, historical evidence concerning human sleep. The meaning of the term „strongest” therefore depends on the outcome being compared.

Do Epitalon, DSIP, SS-31 and NAD+ work better together?

This has not been established. These compounds affect various biological systems, but theoretical complementarity does not prove synergy. To confirm a superior effect of the combination, controlled studies would need to compare each intervention with the combination while assessing pharmacokinetics, safety, and pre-specified outcomes.

Limitations of longevity-related peptide comparisons

The first limitation lies in the category itself. Epitalon, DSIP and elamipretide are peptides, but NAD+ is not; Endoluten, on the other hand, is best described as a peptide complex rather than a single molecule with a defined sequence. Grouping them under the single term „longevity peptides” reflects contemporary search engine user behaviour rather than chemical classification.

The second limitation is the mismatch of endpoints. Epitalon research focuses on telomeres and pineal gland biology; DSIP research focuses on sleep; elamipretide directly affects mitochondrial bioenergetics; whereas NAD precursor studies measure metabolic and NAD-related outcomes. Comparing these compounds solely on the basis of publication count, without considering what was actually measured, can lead to erroneous conclusions.

The third limitation is the difference between biomarkers and clinically relevant outcomes. Epitalon may affect telomeres in cultured cells, NR and NMN can increase the level of NAD-related metabolites, elamipretide can influence mitochondrial function, and DSIP can alter certain sleep parameters. None of these results automatically prove slower biological ageing.

The fourth limitation concerns the age and quality of the evidence. DSIP is unusual because there are direct human clinical trials, but many of these were conducted in the 1980s on very small sample sizes. The literature on Epitalon includes many older studies and a significant concentration of work originating from Khavinson's research network. Elamipretide has a more contemporary randomised clinical trial programme, whereas research into NAD precursors is extensive but heterogeneous.

In the case of DSIP, the route of administration, formulation and molecular form additionally limit interpretation. Historical intravenous studies cannot validate contemporary intranasal, oral or subcutaneous products, and results concerning phospho-DSIP or modified analogues cannot be treated as evidence regarding native DSIP. The lack of contemporary pharmacokinetic programmes, formulation studies, dose-range studies and long-term safety leaves significant uncertainty even where older evidence of biological activity has been reported.

The fifth limitation is the specificity of the indication. The FDA approval of elamipretide for Barth syndrome represents an important milestone in terms of evidence, but it cannot be generalised to healthy individuals seeking mitochondrial or longevity-related effects. Similarly, research on NR or NMN demonstrating an effect on a biochemical target cannot be transformed into proof that a direct NAD+ infusion extends lifespan.

The sixth limitation concerns Endoluten. Search and product terminology often conflate it with Epithalamin and Epitalon despite significant differences in chemical definition and evidence attribution. Until peer-reviewed research specific to Endoluten clearly characterizes the material and assesses it independently, claims borrowed from other preparations require caution.

Finally, evidence regarding combinations is virtually non-existent. Search terms including ‘Epithalon + DSIP’ or multi-component stacks associated with longevity reflect users’ interest rather than established protocols. The diversity of mechanisms may justify investigating combinations, but it cannot replace direct studies of these combinations.

Conclusions

Epitalon, DSIP, SS-31/elamipretide, NAD+ and Endoluten occupy very different positions in ageing and longevity research. Characteristic evidence for Epitalon includes telomerase, telomeres, pineal gland biology and experimental ageing studies. DSIP has been the subject of direct human sleep studies, but reported benefits have been inconsistent and often considered clinically minor. Elamipretide has the strongest conventional clinical development programme and a currently FDA-approved indication, but this specifically addresses Barth syndrome rather than ageing. NAD-directed interventions, particularly NR and NMN, have the broadest contemporary human biomarker literature, whilst clinically meaningful anti-ageing effects remain uncertain. Endoluten has a much less clearly attributable peer-reviewed evidence base than chemically defined Epitalon.

The expanded evidence base concerning DSIP leads to the same conclusion. Historical studies demonstrate biological and sleep-related activity under certain conditions, but do not confirm repeatable efficacy in treating insomnia, a confirmed receptor mechanism, a validated half-life in humans, predictable cortisol reduction, or an extension of human lifespan. When interpreting the literature, findings regarding intravenous DSIP, phospho-DSIP, and contemporary unapproved products should be considered separately.

Most importantly, none of these compounds showed an extension of normal human lifespan. The strongest evidence relates to narrower outcomes — sleep measurements for DSIP, mitochondrial diseases and bioenergetics for elamipretide, NAD-related biomarkers for NR/NMN, and cellular telomere mechanisms for Epitalon.

Because of this, the more scientifically useful question is not „Which longevity-associated peptide is best?”, but rather: „Which compound has direct evidence regarding the specific biological or clinical outcome in question?”.

Disclaimer

The article is strictly of an educational and scientific-information nature and does not constitute medical advice, dosage guidelines, therapeutic recommendations, product selection advice, or a recommendation for the use of Epitalon, DSIP, SS-31/elamipretide, NAD+, Endoluten, or any combination of these compounds. Their evidence bases differ significantly, and preclinical, cellular, or biomarker results should not be interpreted as evidence of anti-ageing or life-extending effects in humans. Elamipretide has a specific FDA-approved indication for certain patients with Barth syndrome and this should not be generalised to healthy ageing or longevity. Experimental doses and routes of administration described in the cited literature represent research details, not instructions for self-administration.

References

[1] Araj, S. K., Brzezik, J., Mądra-Gackowska, K., & Szeleszczuk, Ł. (2025). Overview of Epitalon—Highly bioactive pineal tetrapeptide with promising properties. International Journal of Molecular Sciences, 26(6), 2691.
https://doi.org/10.3390/ijms26062691

[2] Schoenenberger, G. A., Maier, P. F., Tobler, H. J., Wilson, K., & Monnier, M. (1978). The delta EEG (sleep)-inducing peptide (DSIP). XI. Amino-acid analysis, sequence, synthesis and activity of the nonapeptide. Pflügers Archiv, 376(2), 119–129.
https://doi.org/10.1007/BF00581575

[3] Schneider-Helmert, D., Gnirss, F., Monnier, M., Schenker, J., & Schoenenberger, G. A. (1981). Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behaviour. International Journal of Clinical Pharmacology, Therapy and Toxicology, 19(8), 341–345.
https://pubmed.ncbi.nlm.nih.gov/6895513/

[4] Bes, F., Hofman, W., Schuur, J., & Van Boxtel, C. (1992). Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients: A double-blind study. Neuropsychobiology, 26(4), 193–197. https://doi.org/10.1159/000118919

[5] Monti, J. M., Debellis, J., Alterwain, P., Pellejero, T., & Monti, D. (1987). Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs. International Journal of Clinical Pharmacology Research, 7(2), 105–110. https://pubmed.ncbi.nlm.nih.gov/3583493/

[6] Schoenenberger, G. A. (1984). Characterisation, properties and multivariate functions of delta-sleep-inducing peptide (DSIP). European Neurology, 23(5), 321–345. https://doi.org/10.1159/000115711

[7] Vinten, K. T., Trętowicz, M. M., Coskun, E., van Weeghel, M., Cantó, C., Zapata-Pérez, R., Janssens, G. E., & Houtkooper, R. H. (2025). NAD+ precursor supplementation in human ageing: Clinical evidence and challenges. Nature Metabolism, 7(10), 1974–1990.
https://doi.org/10.1038/s42255-025-01387-7

[8] Khavinson, V. K., Kopylov, A. T., Vaskovsky, B. V., Ryzhak, G. A., & Linkova, N. S. (2017). Identification of peptide AEDG in the polypeptide complex of the pineal gland. Bulletin of Experimental Biology and Medicine, 164(1), 41–43.
https://doi.org/10.1007/s10517-017-3922-8

[9] National Center for Biotechnology Information. Delta Sleep-Inducing Peptide. PubChem CID 68816.
https://pubchem.ncbi.nlm.nih.gov/compound/68816

[10] Khavinson, V. K., Bondarev, I. E., & Butyugov, A. A. (2003). Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine, 135(6), 590–592.
https://doi.org/10.1023/A:1025493705728

[11] Al-Dulaimi, S., Thomas, R., Matta, S., & Roberts, T. (2025). Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology, 26(5), Article 178. https://doi.org/10.1007/s10522-025-10315-x

[11a] Al-Dulaimi, S., Thomas, R., Matta, S., & Roberts, T. (2026). Correction: Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology, 27(1), Article 1. https://doi.org/10.1007/s10522-025-10326-8

[12] Khavinson, V. K., Bondarev, I. E., Butyugov, A. A., & Smirnova, T. D. (2004). Peptide promotes overcoming of the division limit in human somatic cell. Bulletin of Experimental Biology and Medicine, 137(5), 503–506. https://doi.org/10.1023/B:BEBM.0000038164.49947.8C

[13] Khavinson, V. K., Lezhava, T. A., Monaselidze, J. R., Jokhadze, T. A., Dvalishvili, N. A., Bablishvili, N. K., & Trofimova, S. V. (2003). Peptide Epitalon activates chromatin at old age. Neuro Endocrinology Letters, 24(5), 329–333.
https://pubmed.ncbi.nlm.nih.gov/14647006/

[14] Goncharova, N. D., Khavinson, V. K., & Lapin, B. A. (2001). Regulatory effect of Epithalon on production of melatonin and cortisol in old monkeys. Bulletin of Experimental Biology and Medicine, 131(4), 394–396.
https://doi.org/10.1023/A:1017928925177

[15] Khavinson, V. K., Linkova, N. S., Kvetnoy, I. M., Kvetnaia, T. V., Polyakova, V. O., & Korf, H.-W. (2012). Molecular cellular mechanisms of peptide regulation of melatonin synthesis in pinealocyte culture. Bulletin of Experimental Biology and Medicine, 153(2), 255–258.
https://doi.org/10.1007/s10517-012-1689-5

[16] Djeridane, Y., Khavinson, V. K., Anisimov, V. N., & Touitou, Y. (2003). Effect of a synthetic pineal tetrapeptide (Ala-Glu-Asp-Gly) on melatonin secretion by the pineal gland of young and old rats. Journal of Endocrinological Investigation, 26(3), 211–215.
https://doi.org/10.1007/BF03345159

[17] Scherschlicht, R., Aeppli, L., Polc, P., & Haefely, W. (1984). Some pharmacological effects of delta-sleep-inducing peptide (DSIP). European Neurology, 23(5), 346–352.
https://doi.org/10.1159/000115712

[18] Birk, A. V., Liu, S., Soong, Y., Mills, W., Singh, P., Warren, J. D., Seshan, S. V., Pardee, J. D., & Szeto, H. H. (2013). The mitochondrial-targeted compound SS-31 re-energises ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology, 24(8), 1250–1261. https://doi.org/10.1681/ASN.2012121216

[18a] Birk, A. V., Chao, W. M., Bracken, C., Warren, J. D., & Szeto, H. H. (2014). Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimise mitochondrial ATP synthesis. British Journal of Pharmacology, 171(8), 2017–2028. https://doi.org/10.1111/bph.12468

[19] Karaa, A., Haas, R., Goldstein, A., Vockley, J., Weaver, W. D., & Cohen, B. H. (2018). Randomised dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology, 90(14), e1212–e1221. https://doi.org/10.1212/WNL.0000000000005255

[20] Karaa, A., Haas, R., Goldstein, A., Vockley, J., & Cohen, B. H. (2020). A randomised crossover trial of elamipretide in adults with primary mitochondrial myopathy. Journal of Cachexia, Sarcopenia and Muscle, 11(4), 909–918.
https://doi.org/10.1002/jcsm.12559

[21] Butler, J., Khan, M. S., Anker, S. D., Fonarow, G. C., Kim, R. J., Nodari, S., O’Connor, C. M., Pieske, B., Pieske-Kraigher, E., Sabbah, H. N., Senni, M., Voors, A. A., Udelson, J. E., Carr, J., Gheorghiade, M., & Filippatos, G. (2020). Effects of elamipretide on left ventricular function in patients with heart failure with reduced ejection fraction: The PROGRESS-HF phase 2 trial. Journal of Cardiac Failure, 26(5), 429–437.
https://doi.org/10.1016/j.cardfail.2020.02.001

[22] Roshanravan, B., Liu, S. Z., Ali, A. S., Shankland, E. G., Goss, C., Amory, J. K., Robertson, H. T., Marcinek, D. J., & Conley, K. E. (2021). In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomised trial. PLOS ONE, 16(7), e0253849. https://doi.org/10.1371/journal.pone.0253849

[23] Thompson, W. R., Hornby, B., Manuel, R., Bradley, E., Laux, J., Carr, J., & Vernon, H. J. (2021). A phase 2/3 randomised clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genetics in Medicine, 23(3), 471–478.
https://doi.org/10.1038/s41436-020-01006-8

[24] Zhang, J., Wang, H.-L., Lautrup, S., Nilsen, H. L., Treebak, J. T., Watne, L. O., Selbæk, G., Wu, L. E., Omland, T., Pirinen, E., et al. (2025). Emerging strategies, applications and challenges of targeting NAD+ in the clinic. Nature Aging, 5(9), 1704–1731. https://doi.org/10.1038/s43587-025-00947-6

[25] Gallagher, C., & Emmanuel, O. O. (2026). NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Research Reviews, 116, 103057. https://doi.org/10.1016/j.arr.2026.103057

[26] Freeberg, K. A., Udovich, C. A. C., Martens, C. R., Seals, D. R., & Craighead, D. H. (2023). Dietary supplementation with NAD+-boosting compounds in humans: Current knowledge and future directions. The Journals of Gerontology: Series A, 78(12), 2435–2448. https://doi.org/10.1093/gerona/glad106

[27] Bhasin, S., Seals, D., Migaud, M., Musi, N., & Baur, J. A. (2023). Nicotinamide adenine dinucleotide in aging biology: Potential applications and many unknowns. Endocrine Reviews, 44(6), 1047–1073. https://doi.org/10.1210/endrev/bnad019

[27a] Covarrubias, A. J., Perrone, R., Grozio, A., & Verdin, E. (2021). NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology, 22(2), 119–141. https://doi.org/10.1038/s41580-020-00313-x

[28] Khavinson, V. K., Linkova, N. S., & Tarnovskaya, S. I. (2016). Short peptides regulate gene expression. Bulletin of Experimental Biology and Medicine, 162(2), 288–292.
https://doi.org/10.1007/s10517-016-3596-7